期刊
MOVEMENT DISORDERS
卷 25, 期 12, 页码 1801-1808出版社
WILEY
DOI: 10.1002/mds.23006
关键词
Melanoma; cancer; L-dopa; Parkinson's disease; apoptosis
资金
- Cephalon, Inc. (Frazer, PA)
- H. Lundbeck A/S (Copenhagen, Denmark)
- National Center for Research Resources (NCRR), National Institutes of Health (NIH) [UL1 RR 025005]
- NIH Roadmap for Medical Research
We performed a placebo-controlled trial of CEP1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long-term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP-1347. Patients were monitored for an average of 1.8 years (1,467 patient-years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP-1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP-1347 affected cancer incidence within 2 years of follow-up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. (C) 2010 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据